Thomas F Newton

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3927097/publications.pdf

Version: 2024-02-01

126708 123241 4,245 103 33 61 citations h-index g-index papers 103 103 103 4334 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	In Cocaine Dependence, Neural Prediction Errors During Loss Avoidance Are Increased With Cocaine Deprivation and Predict Drug Use. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 2019, 4, 291-299.	1.1	14
2	Guanfacine Attenuates Adverse Effects of Dronabinol (THC) on Working Memory in Adolescent-Onset Heavy Cannabis Users: A Pilot Study. Journal of Neuropsychiatry and Clinical Neurosciences, 2018, 30, 66-76.	0.9	10
3	Comparison of three measurement models of discounting among individuals with methamphetamine use disorder. American Journal on Addictions, 2018, 27, 425-432.	1.3	13
4	FAAH variant Pro129Thr modulates subjective effects produced by cocaine administration. American Journal on Addictions, 2018, 27, 567-573.	1.3	10
5	Electrocardiographic characteristics in individuals with cocaine use disorder. American Journal on Addictions, 2017, 26, 221-227.	1.3	4
6	Genetic moderation of cocaine subjective effects by variation in the TPH1, TPH2, and SLC6A4 serotonin genes. Psychiatric Genetics, 2017, 27, 178-186.	0.6	5
7	A Comparison of Mazur's k and Area Under the Curve for Describing Steep Discounters. Psychological Record, 2017, 67, 355-363.	0.6	19
8	The limited impact that cocaine use patterns have on neurocognitive functioning in individuals with cocaine use disorder. Journal of Psychopharmacology, 2017, 31, 989-995.	2.0	5
9	The relationship between premorbid IQ and neurocognitive functioning in individuals with cocaine use disorders Neuropsychology, 2017, 31, 311-318.	1.0	10
10	The \hat{l}_{\pm} -1 adrenoceptor (ADRA1A) genotype moderates the magnitude of acute cocaine-induced subjective effects in cocaine-dependent individuals. Pharmacogenetics and Genomics, 2016, 26, 428-435.	0.7	5
11	Subjective and Cardiovascular Effects of Intravenous Methamphetamine during Perindopril Maintenance: A Randomized, Double-Blind, Placebo-Controlled Human Laboratory Study. International Journal of Neuropsychopharmacology, 2016, 19, pyw029.	1.0	12
12	Treadmill exercise improves fitness and reduces craving and use of cocaine in individuals with concurrent cocaine and tobacco-use disorder. Psychiatry Research, 2016, 245, 133-140.	1.7	34
13	Cocaine cardiovascular effects and pharmacokinetics after treatment with the acetylcholinesterase inhibitor donepezil. American Journal on Addictions, 2016, 25, 392-399.	1.3	1
14	Safety and Preliminary Efficacy of the Acetylcholinesterase Inhibitor Huperzine A as a Treatment for Cocaine Use Disorder. International Journal of Neuropsychopharmacology, 2016, 19, pyv098.	1.0	13
15	Application of programmable bio-nano-chip system for the quantitative detection of drugs of abuse in oral fluids. Drug and Alcohol Dependence, 2015, 153, 306-313.	1.6	28
16	Evaluation of the dopamine \hat{I}^2 -hydroxylase (D \hat{I}^2 H) inhibitor nepicastat in participants who meet criteria for cocaine use disorder. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2015, 59, 40-48.	2.5	18
17	A comparison of impulsivity, depressive symptoms, lifetime stress and sensation seeking in healthy controls versus participants with cocaine or methamphetamine use disorders. Journal of Psychopharmacology, 2015, 29, 50-56.	2.0	63
18	Dopamine D3 receptor-preferring agonist enhances the subjective effects of cocaine in humans. Psychiatry Research, 2015, 230, 44-49.	1.7	10

#	Article	IF	Citations
19	Genetic variation of the dopamine transporter (DAT1) influences the acute subjective responses to cocaine in volunteers with cocaine use disorders. Pharmacogenetics and Genomics, 2015, 25, 296-304.	0.7	24
20	Next Generation Programmable Bio-Nano-Chip System for On-Site Detection in Oral Fluids. Journal of Drug Abuse, 2015, 1, 1-6.	0.2	3
21	Choosing Money over Drugs: The Neural Underpinnings of Difficult Choice in Chronic Cocaine Users. Journal of Addiction, 2014, 2014, 1-14.	0.9	21
22	Safety and efficacy of varenicline to reduce positive subjective effects produced by methamphetamine in methamphetamine-dependent volunteers. International Journal of Neuropsychopharmacology, 2014, 17, 223-233.	1.0	18
23	A variant in <i><scp>ANKK1</scp></i> modulates acute subjective effects of cocaine: a preliminary study. Genes, Brain and Behavior, 2014, 13, 559-564.	1.1	16
24	Assessment of safety, cardiovascular and subjective effects after intravenous cocaine and lofexidine. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2014, 50, 44-52.	2.5	4
25	The relationship between sleep and drug use characteristics in participants with cocaine or methamphetamine use disorders. Psychiatry Research, 2014, 219, 367-371.	1.7	37
26	Treatment with modafinil and escitalopram, alone and in combination, on cocaine-induced effects: A randomized, double blind, placebo-controlled human laboratory study. Drug and Alcohol Dependence, 2014, 141, 72-78.	1.6	39
27	Plasma brain derived neurotrophic factor (BDNF) and response to ketamine in treatment-resistant depression. International Journal of Neuropsychopharmacology, 2014, 17, 331-336.	1.0	195
28	The impact of self-reported life stress on current impulsivity in cocaine dependent adults. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2013, 46, 113-119.	2.5	11
29	Individual predictors of the subjective effects of intravenous cocaine. Psychiatry Research, 2013, 208, 245-251.	1.7	6
30	The influence of smoking cigarettes on the high and desire for cocaine among active cocaine users. Pharmacology Biochemistry and Behavior, 2013, 106, 132-136.	1.3	24
31	Pharmacotherapeutics for substance-use disorders: a focus on dopaminergic medications. Expert Opinion on Investigational Drugs, 2013, 22, 1549-1568.	1.9	28
32	Effects of methamphetamine on the noradrenergic activity biomarker salivary alpha-amylase. Drug and Alcohol Dependence, 2013, 133, 759-762.	1.6	5
33	The relationship between lifetime stress and addiction severity in cocaine-dependent participants. European Neuropsychopharmacology, 2013, 23, 351-357.	0.3	18
34	Effects of D-cycloserine on cue-induced craving and cigarette smoking among concurrent cocaine-and nicotine-dependent volunteers. Addictive Behaviors, 2013, 38, 1518-1526.	1.7	27
35	A Comparison of the Subjective and Cardiovascular Effects Produced by Exposure to Intravenous versus Smoked Methamphetamine in the Laboratory. FASEB Journal, 2013, 27, 1098.13.	0.2	0
36	Subjective and Cardiovascular Responses to Cocaine Differ in Cigarette Smokers versus Nonsmokers. FASEB Journal, 2013, 27, 659.17.	0.2	0

3

#	Article	IF	CITATIONS
37	The Impact of Disulfiram Treatment on the Reinforcing Effects of Cocaine: A Randomized Clinical Trial. PLoS ONE, 2012, 7, e47702.	1.1	22
38	Acute modafinil exposure reduces daytime sleepiness in abstinent methamphetamine-dependent volunteers. International Journal of Neuropsychopharmacology, 2012, 15, 1241-1249.	1.0	22
39	Rivastigmine reduces "likely to use methamphetamine―in methamphetamine-dependent volunteers. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2012, 37, 141-146.	2.5	27
40	d-Cycloserine administration does not affect neurocognition in concurrent cocaine- and nicotine-dependent volunteers. Pharmacology Biochemistry and Behavior, 2012, 103, 403-407.	1.3	2
41	The $\hat{l}\pm 1$ Antagonist Doxazosin Alters the Behavioral Effects of Cocaine in Rats. Brain Sciences, 2012, 2, 619-633.	1.1	12
42	Pharmacotherapeutics directed at deficiencies associated with cocaine dependence: Focus on dopamine, norepinephrine and glutamate., 2012, 134, 260-277.		47
43	Noradrenergic $\hat{l}\pm 1$ Receptor Antagonist Treatment Attenuates Positive Subjective Effects of Cocaine in Humans: A Randomized Trial. PLoS ONE, 2012, 7, e30854.	1.1	48
44	VIRTUAL REALITY CUE EXPOSURE THERAPY FOR THE TREATMENT OF TOBACCO DEPENDENCE. Journal of Cybertherapy & Rehabilitation, 2012, 5, 57-64.	1.7	21
45	A double-blind, placebo-controlled assessment of the safety of potential interactions between intravenous cocaine, ethanol, and oral disulfiram. Drug and Alcohol Dependence, 2011, 119, 37-45.	1.6	19
46	Acute, low-dose methamphetamine administration improves attention/information processing speed and working memory in methamphetamine-dependent individuals displaying poorer cognitive performance at baseline. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2011, 35, 459-465.	2.5	22
47	The relationship between impulsivity and craving in cocaine- and methamphetamine-dependent volunteers. Pharmacology Biochemistry and Behavior, 2011, 98, 196-202.	1.3	51
48	Methamphetamine craving induced in an online virtual reality environment. Pharmacology Biochemistry and Behavior, 2010, 96, 454-460.	1.3	101
49	Relationship between gender and psychotic symptoms in cocaine-dependent and methamphetamine-dependent participants. Gender Medicine, 2010, 7, 414-421.	1.4	41
50	Modafinil Administration Improves Working Memory in Methamphetamineâ€Dependent Individuals Who Demonstrate Baseline Impairment. American Journal on Addictions, 2010, 19, 340-344.	1.3	55
51	Methamphetamine Cured my Cocaine Addiction. Journal of Addiction Research & Therapy, 2010, 01, .	0.2	3
52	Evaluation of modafinil effects on cardiovascular, subjective, and reinforcing effects of methamphetamine in methamphetamine-dependent volunteers. Drug and Alcohol Dependence, 2010, 106, 173-180.	1.6	55
53	Donepezil treatment and the subjective effects of intravenous cocaine in dependent individuals. Drug and Alcohol Dependence, 2010, 107, 69-75.	1.6	20
54	The angiotensin-converting enzyme inhibitor perindopril treatment alters cardiovascular and subjective effects of methamphetamine in humans. Psychiatry Research, 2010, 179, 96-100.	1.7	9

#	Article	IF	CITATIONS
55	Pilot Safety Evaluation of Varenicline for the Treatment of Methamphetamine Dependence. FASEB Journal, 2010, 24, 580.2.	0.2	0
56	Pilot safety evaluation of varenicline for the treatment of methamphetamine dependence. Journal of Experimental Pharmacology, 2010, 2, 13-8.	1.5	12
57	A Liquid Chromatography-Electrospray Ionization-Tandem Mass Spectrometry Method for Quantitation of Aripiprazole in Human Plasma. Journal of Analytical Toxicology, 2009, 33, 237-242.	1.7	18
58	The cardiovascular and subjective effects of methamphetamine combined with γ-vinyl-γ-aminobutyric acid (GVG) in non-treatment seeking methamphetamine-dependent volunteers. Pharmacology Biochemistry and Behavior, 2009, 94, 186-193.	1.3	18
59	Theories of Addiction: Methamphetamine Users' Explanations for Continuing Drug Use and Relapse. American Journal on Addictions, 2009, 18, 294-300.	1.3	70
60	Influence of Verbal Recall of a Recent Stress Experience on Anxiety and Desire for Cocaine in Non-Treatment Seeking, Cocaine-Addicted Volunteers. American Journal on Addictions, 2009, 18, 481-487.	1.3	7
61	Quantitative EEG Abnormalities are Associated With Memory Impairment in Recently Abstinent Methamphetamine-Dependent Individuals. Journal of Neuropsychiatry and Clinical Neurosciences, 2009, 21, 254-258.	0.9	22
62	Predictors of Cardiovascular Response to Methamphetamine Administration in Methamphetamine-Dependent Individuals. American Journal on Addictions, 2008, 17, 103-110.	1.3	8
63	Presence and Persistence of Psychotic Symptoms in Cocaine- versus Methamphetamine-Dependent Participants. American Journal on Addictions, 2008, 17, 83-98.	1.3	84
64	The acetylcholinesterase inhibitor rivastigmine does not alter total choices for methamphetamine, but may reduce positive subjective effects, in a laboratory model of intravenous self-administration in human volunteers. Pharmacology Biochemistry and Behavior, 2008, 89, 200-208.	1.3	45
65	Evaluation of the cardiovascular and subjective effects of rivastigmine in combination with methamphetamine-dependent human volunteers. International Journal of Neuropsychopharmacology, 2008, 11, 729-41.	1.0	33
66	Evaluation of subjective effects of aripiprazole and methamphetamine in methamphetamine-dependent volunteers. International Journal of Neuropsychopharmacology, 2008, 11, 1037.	1.0	51
67	Pathological Gamblers Demonstrate Frontal Lobe Impairment Consistent With That of Methamphetamine-Dependent Individuals. Journal of Neuropsychiatry and Clinical Neurosciences, 2007, 19, 298-303.	0.9	37
68	Subjective and cardiovascular effects of cocaine during treatment with amantadine and baclofen in combination. Psychiatry Research, 2007, 152, 205-210.	1.7	19
69	A qualitative and quantitative review of cocaine-induced craving: The phenomenon of priming. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2007, 31, 593-599.	2.5	25
70	MDMA use and neurocognition: a meta-analytic review. Psychopharmacology, 2007, 189, 531-537.	1.5	111
71	Adherence to antiretroviral medications in HIV: Differences in data collected via self-report and electronic monitoring Health Psychology, 2006, 25, 329-335.	1.3	53
72	Bupropion Reduces Methamphetamine-Induced Subjective Effects and Cue-Induced Craving. Neuropsychopharmacology, 2006, 31, 1537-1544.	2.8	141

#	Article	lF	CITATIONS
73	A Case Report of Topiramate in the Treatment of Nonparaphilic Sexual Addiction. Journal of Clinical Psychopharmacology, 2005, 25, 512-514.	0.7	27
74	Cocaine and methamphetamine produce different patterns of subjective and cardiovascular effects. Pharmacology Biochemistry and Behavior, 2005, 82, 90-97.	1.3	99
75	Apathy predicts hedonic but not craving response to cocaine. Pharmacology Biochemistry and Behavior, 2005, 82, 236-240.	1.3	7
76	A comprehensive assessment of the safety of intravenous methamphetamine administration during treatment with selegiline. Pharmacology Biochemistry and Behavior, 2005, 82, 704-711.	1.3	20
77	Risperidone diminishes cocaine-induced craving. Psychopharmacology, 2005, 178, 347-350.	1.5	26
78	Safety of intravenous methamphetamine administration during treatment with bupropion. Psychopharmacology, 2005, 182, 426-435.	1.5	58
79	Variations in Patterns of Highly Active Antiretroviral Therapy (HAART) Adherence. AIDS and Behavior, 2005, 9, 355-362.	1.4	63
80	Mood Disturbances and Regional Cerebral Metabolic Abnormalities inRecently Abstinent Methamphetamine Abusers. Archives of General Psychiatry, 2004, 61, 73.	13.8	346
81	Methamphetamine Abstinence Syndrome: Preliminary Findings. American Journal on Addictions, 2004, 13, 248-255.	1.3	180
82	Transdermal selegiline and intravenous cocaine: safety and interactions. Psychopharmacology, 2004, 172, 31-40.	1.5	32
83	Association between quantitative EEG and neurocognition in methamphetamine-dependent volunteers. Clinical Neurophysiology, 2004, 115, 194-198.	0.7	53
84	Quantitative EEG abnormalities in recently abstinent methamphetamine dependent individuals. Clinical Neurophysiology, 2003, 114, 410-415.	0.7	96
85	Irritability following abstinence from cocaine predicts euphoric effects of cocaine administration. Addictive Behaviors, 2003, 28, 817-821.	1.7	29
86	Apathy syndrome in cocaine dependence. Psychiatry Research, 2002, 109, 97-100.	1.7	27
87	Risperidone pre-treatment reduces the euphoric effects of experimentally administered cocaine. Psychiatry Research, 2001, 102, 227-233.	1.7	59
88	Psychiatric Comorbidity of Methamphetamine Dependence in a Forensic Sample. Journal of Neuropsychiatry and Clinical Neurosciences, 2000, 12, 480-484.	0.9	95
89	Selegiline Effects on Cocaine-Induced Changes in Medial Temporal Lobe Metabolism and Subjective Ratings of Euphoria. Neuropsychopharmacology, 1999, 20, 582-590.	2.8	39
90	Effects of selegiline pretreatment on response to experimental cocaine administration. Psychiatry Research, 1999, 87, 101-106.	1.7	20

#	Article	IF	CITATIONS
91	Cocaine Infusion Increases Interferon- $\hat{1}^3$ and Decreases Interleukin-10 in Cocaine-Dependent Subjects. Clinical Immunology and Immunopathology, 1998, 89, 181-190.	2.1	47
92	Quantitative EEG Effects of Nicotine Replacement by Cigarette Smoking < sup > 1 < /sup > . Neuropsychobiology, 1998, 37, 112-116.	0.9	7
93	The face of craving? Facial muscle EMG and reported craving in abstinent and non-abstinent cocaine users. Psychiatry Research, 1997, 73, 115-118.	1.7	5
94	Reduced EEG coherence in dementia: State or trait marker?. Biological Psychiatry, 1994, 35, 870-879.	0.7	97
95	Electroencephalographic coherence in acquired immune deficiency syndrome. Psychiatry Research, 1994, 54, 1-11.	1.7	9
96	Assessment of cerebral perfusion using quantitative EEG cordance. Psychiatry Research - Neuroimaging, 1994, 55, 141-152.	0.9	32
97	Cordance: A New Method for Assessment of Cerebral Perfusion and Metabolism Using Quantitative Electroencephalography. Neurolmage, 1994, 1, 208-219.	2.1	121
98	Quantitative EEG Correlates of Outcome in Older Psychiatric Patients: Part I: Cross-Sectional and Longitudinal Assessment of Patients With Dementia. American Journal of Geriatric Psychiatry, 1994, 2, 200-209.	0.6	9
99	Quantitative EEG Correlates of Outcome in Older Psychiatric Patients: Part II: Two-Year Follow-Up of Patients With Depression. American Journal of Geriatric Psychiatry, 1994, 2, 290-299.	0.6	10
100	Regional differences in brain electrical activity in dementia: use of spectral power and spectral ratio measures. Electroencephalography and Clinical Neurophysiology, 1993, 87, 385-393.	0.3	171
101	CHANGES IN BRAIN FUNCTIONAL CONNECTIVITY IN ALZHEIMER-TYPE AND MULTI-INFARCT DEMENTIA. Brain, 1992, 115, 1543-1561.	3.7	215
102	EEG sleep in outpatients with generalized anxiety: A preliminary comparison with depressed outpatients. Psychiatry Research, 1983, 8, 81-89.	1.7	131
103	Electroencephalographic sleep findings in depressed outpatients. Psychiatry Research, 1982, 6, 65-75.	1.7	34